Press Release: Macrocure’s CureXcell Shows Strong Efficacy and Safety in Phase IV Hard-To-Heal Wounds Trial Quote: Macrocure ( www.macrocure.com ), a biotechnology company developing and selling advanced cell therapy products, announced today it has achieved positive results for a “Real Life” Phase IV trial of its lead product, CureXcell®, for the treatment of hard-to-heal ulcers in a community care setting.
Read more:
CureXcell for hard-to-heal wounds
Related posts:
